SEMG2

Across TCGA pan-cancer cohorts, SEMG2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SEMG2 data layer compared with 15 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SEMG2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SEMG2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, HNSC, and CCRCC are the cancer types where SEMG2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.560	0.249	.008	16	view →
HNSC	DFS	Median	All	0.402	0.821	.018	7	view →
CCRCC	DFS	Median	All	0.492	1.000	.015	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SEMG2–PDAC (DFS)

Open the PDAC breakdown →